Pitcairn Co. Sells 3,417 Shares of AbbVie Inc. $ABBV

Pitcairn Co. lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 10.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,940 shares of the company’s stock after selling 3,417 shares during the quarter. AbbVie makes up approximately 0.5% of Pitcairn Co.’s investment portfolio, making the stock its 29th largest position. Pitcairn Co.’s holdings in AbbVie were worth $6,701,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in ABBV. Vanguard Group Inc. lifted its holdings in shares of AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after purchasing an additional 448,554 shares during the period. Geode Capital Management LLC raised its position in AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after buying an additional 1,517,222 shares during the period. Norges Bank acquired a new position in AbbVie during the 2nd quarter worth about $4,288,200,000. Finally, Raymond James Financial Inc. grew its position in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Morgan Stanley raised their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Barclays initiated coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Piper Sandler upped their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 AFFIRM results for risankizumab in moderately‑to‑severely active Crohn’s disease — higher clinical remission and endoscopic response vs. placebo, which could expand label/market for a high‑value asset and support longer‑term revenue growth. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: AbbVie advances venetoclax into a Phase 2 program for rare blood cancers in Japan — expands oncology pipeline and potential incremental revenue streams if studies read out positively. AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) highlights Medical Weight Loss data showing shifting patient demand — supports the aesthetics growth narrative and diversification beyond immunology. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
• Positive Sentiment: Operationally constructive: AbbVie expansion reported to boost supply resilience for immunology medicines — lowers execution/supply risk for key franchises. AbbVie (NYSE:ABBV) Expansion Boosts Supply Resilience For Immunology Medicines
• Positive Sentiment: Third‑party bullish coverage and cash‑flow narratives emphasize AbbVie’s strong free cash flow and dividend profile — supportive for income investors and valuation stability. AbbVie: The Only Big Pharma Stock I’d Consider a Buy‑and‑Never‑Sell
• Neutral Sentiment: Corporate presentation/transcript from AbbVie at TD Cowen — may contain incremental detail on strategy and pipeline but no singular catalyst reported in the summary. AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Technical/market commentary notes the stock stabilizing near ~$233 while testing resistance levels — useful for short‑term traders but not a fundamental driver. AbbVie: Stabilizes Near $233 While Testing Resistance
• Neutral Sentiment: Market note reporting AbbVie’s share move relative to the broader market — descriptive of price action rather than a new driver. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
• Negative Sentiment: Large senior notes offering (~$7.5–$8.0B) announced/completed — raises concerns about increased leverage and near‑term debt servicing; markets often view sizable debt raises as a near‑term negative for equity. AbbVie Completes $8 Billion Senior Notes Financing Offering AbbVie Announces $7.5 Billion Senior Notes Offering
• Negative Sentiment: AbbVie lost a bid to block Tennessee’s 340B law — regulatory/policy risk that could pressure pricing/reimbursements and is a negative for revenue in affected programs. AbbVie loses bid to block Tennessee 340B law

AbbVie Stock Performance

AbbVie stock opened at $232.07 on Friday. The stock has a market capitalization of $410.34 billion, a price-to-earnings ratio of 98.33, a PEG ratio of 0.82 and a beta of 0.34. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock’s 50 day moving average price is $224.72 and its two-hundred day moving average price is $223.80.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.